These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30152284)

  • 1. Current Progress on Peroxisome Proliferator-activated Receptor Gamma Agonist as an Emerging Therapeutic Approach for the Treatment of Alzheimer's Disease: An Update.
    Khan MA; Alam Q; Haque A; Ashafaq M; Khan MJ; Ashraf GM; Ahmad M
    Curr Neuropharmacol; 2019; 17(3):232-246. PubMed ID: 30152284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease.
    Landreth G; Jiang Q; Mandrekar S; Heneka M
    Neurotherapeutics; 2008 Jul; 5(3):481-9. PubMed ID: 18625459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications.
    Jiang Q; Heneka M; Landreth GE
    CNS Drugs; 2008; 22(1):1-14. PubMed ID: 18072811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice.
    Skerrett R; Pellegrino MP; Casali BT; Taraboanta L; Landreth GE
    J Biol Chem; 2015 Aug; 290(35):21591-602. PubMed ID: 26163517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.
    Mandrekar-Colucci S; Karlo JC; Landreth GE
    J Neurosci; 2012 Jul; 32(30):10117-28. PubMed ID: 22836247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice.
    Yamanaka M; Ishikawa T; Griep A; Axt D; Kummer MP; Heneka MT
    J Neurosci; 2012 Nov; 32(48):17321-31. PubMed ID: 23197723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor-gamma agonists for Alzheimer's disease and amnestic mild cognitive impairment: a systematic review and meta-analysis.
    Liu J; Wang LN; Jia JP
    Drugs Aging; 2015 Jan; 32(1):57-65. PubMed ID: 25504005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alzheimer's disease].
    Hanyu H; Sato T
    Nihon Rinsho; 2010 Feb; 68(2):330-4. PubMed ID: 20158105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.
    Watson GS; Craft S
    CNS Drugs; 2003; 17(1):27-45. PubMed ID: 12467491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in-silico approach: identification of PPAR-γ agonists from seaweeds for the management of Alzheimer's Disease.
    Kotha S; B S; Kulkarni VM; S RS; B HK; R H
    J Biomol Struct Dyn; 2021 Apr; 39(6):2210-2229. PubMed ID: 32216605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review on the development in the field of NIDDM based thiazolidinedione PPARγ agonists.
    Banerjee PS; Samanta S
    Mini Rev Med Chem; 2013 Apr; 13(5):706-12. PubMed ID: 22512587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
    Cho N; Momose Y
    Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.
    Schinner S; Krätzner R; Baun D; Dickel C; Blume R; Oetjen E
    Br J Pharmacol; 2009 Jul; 157(5):736-45. PubMed ID: 19338578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease.
    Landreth G
    Curr Alzheimer Res; 2007 Apr; 4(2):159-64. PubMed ID: 17430241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
    Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
    J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone for the treatment of Alzheimer's disease.
    Galimberti D; Scarpini E
    Expert Opin Investig Drugs; 2017 Jan; 26(1):97-101. PubMed ID: 27885860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.